Novo Nordisk Raises Outlook as Wegovy Pill Sales Reach DKK 5.4 Billion
Wegovy pill revenue and stronger cash-flow guidance lift Novo’s recovery case. Impairment charges and U.S. pricing pressure complicate the earnings picture.
Novo Nordisk raised its annual sales and operating-profit outlook on November 4 after quarterly revenue from its Wegovy weight-loss pill reached DKK 5.394 billion. The result gives the Danish drugmaker a stronger commercial footing in oral obesity treatments, while its financial statements show how much of the recovery still depends on pricing, manufacturing decisions and the distinction between adjusted and reported earnings.
The company now expects 2026 adjusted sales and adjusted operating profit to range from a 2% decline to 2% growth at constant exchange rates. Its August forecast had allowed for a decline of as much as 6%, with an upper end of zero growth. The revision therefore improves both ends of the range, rather than guaranteeing a return to expansion. Total quarterly sales reached DKK 79.195 billion, up 4% at constant exchange rates.
The pill is becoming a meaningful contributor
Wegovy pill had reached four markets by the end of September, with subsequent launches bringing the total to eight. Reuters reported that quarterly pill sales exceeded a DKK 4.62 billion analyst consensus. That is an important comparison for expectations, although the contribution of one product cannot by itself establish the direction of the entire business.
The detailed quarterly report puts U.S. pill revenue at DKK 4.178 billion and international revenue at DKK 1.216 billion. Around 3.6 million U.S. prescriptions were recorded during the quarter. The geographic split shows that the existing U.S. business still supplied most of the pill’s revenue, even as additional launches broadened the opportunity outside that market.
Prescriptions and revenue measure different parts of the rollout. More prescriptions can indicate adoption, while sales also reflect doses, channel mix and the amount the manufacturer actually realizes. For an investor, the useful comparison over subsequent quarters will be whether additional volume translates into incremental earnings after distribution, production and commercial expenses.
An oral product also gives Novo another way to reach customers within its own portfolio. That creates a possible source of growth and a potential shift between product formats. Total franchise performance matters when judging the result: revenue that moves from an injectable product to a pill has a different financial meaning from revenue generated by a newly treated patient.
Adjusted growth and reported profit tell different stories
Third-quarter adjusted operating profit was DKK 31.720 billion, up 27% at constant exchange rates. Reported operating profit was DKK 23.011 billion, down 9% on the same currency basis. Novo identified DKK 8.7 billion of non-cash impairments, including DKK 4.6 billion related to ziltivekimab and DKK 4.1 billion associated with its manufacturing network.
The year-earlier comparison also included DKK 9 billion of transformation costs. That makes the 27% adjusted-profit increase an incomplete measure of fresh operating momentum if considered without the comparison base. The charges, definitions and timing all need to accompany the headline growth rate.
A non-cash impairment does not require an equivalent payment in the quarter it is recognized. It nevertheless records a reduction in the carrying value of assets built or acquired with earlier investment. Excluding that charge can help assess current trading, but it does not eliminate the investment outcome. The gap between the two profit measures deserves attention precisely because Novo is reshaping its product and manufacturing base.
Cash guidance improves, with a demanding fourth-quarter bridge
Novo lifted its full-year free-cash-flow forecast to DKK 60 billion–70 billion from DKK 45 billion–55 billion. It also reduced expected capital expenditure to around DKK 50 billion from DKK 55 billion. The company reported DKK 83.8 billion of free cash flow in the first nine months, citing payment timing and lower investment spending among the drivers.
The year-to-date figure is already above the new annual range. Simple subtraction implies fourth-quarter free cash flow of roughly negative DKK 23.8 billion to negative DKK 13.8 billion if the annual forecast is met. That is an arithmetic implication of the guidance, not a separate company forecast for the quarter. It makes the timing of expenditure and other cash movements especially relevant to the final result.
As TTN Finance explains in its guide to free cash flow, definitions and payment timing, cash generated during one reporting period cannot automatically be treated as a sustainable annual run rate. In this case, the improved forecast strengthens Novo’s capacity to fund investment and shareholder distributions, while the quarterly bridge prevents an overly optimistic reading of the nine-month total.
The detailed outlook also anticipates a U.S. sales decline for the year, offset by international growth. More volume is therefore being pursued against pressure on realized prices. That combination matters for a high-margin drug business: expanding patient access can support long-term demand, while each additional unit may contribute less revenue than the last.
Novo’s upgrade provides evidence that the pill launch is contributing financially and that cash expectations have improved. The next assessment will depend on the quality of that growth: total portfolio sales, pricing and conversion into cash after investment. A stronger product launch helps the recovery case; the reported accounts show why that case still requires more than a single adjusted-profit percentage.